Sorin today announced it received FDA approval for and is beginning the U.S. launch of the SMARTVIEW™ remote monitoring solution for patients with CRM devices. From the press release: “Using the secure SMARTVIEW remote monitoring solution, physicians and nurses following patients with a Sorin PARADYMTM RF device can access valuable cardiac data and alert messages from
Comments Off 
Sorin Receives Conditional FDA IDE Approval to Study its Paradym CRT-D IPG and SonRtip Hemodynamic Sensor Lead
Sorin announced it received U.S. Food and Drug Administration (FDA) conditional approval for its Investigational Device Exemption (IDE) application and clinical trial protocol for RESPOND CRT. The trial will study the safety and effectiveness of the innovative SonR cardiac resynchronization therapy (CRT) optimization system in patients with advanced heart failure. RESPOND CRT is a multi-center,
Comments Off
Glucose Fuel-Cell-Powered Implantable Devices
My friend, Dr. Alain Ripart - the Chief Scientific Officer at Ela Medical (now part of Sorin) showed me this interesting contraption from his personal collection. It is an experimental glucose-powered pacemaker developed in the 1970s. It generated electricity by acquiring its fuel (glucose) directly from a living body to generate enough current to charge two NiCd cells
Comments Off
